OVERALL ABSTRACT The NCI-designated UCLA Jonsson Comprehensive Cancer Center (JCCC) resides within the most populous, most diverse county in the US, with a mission to accelerate discoveries that prevent and cure cancer. Through a broad spectrum of research, education, training, and community engagement activities, the Center strives to reduce the burden of cancer in its Los Angeles County (LAC) catchment area, nationally, and globally by improving the standards for cancer prevention, detection, treatment, control, and survivorship. To advance its mission, the Center supports three Basic/Translational Research Programs (Epigenomics, RNA & Gene Regulation (ERGR); Cancer & Stem Cell Biology (CSCB); Cancer Molecular Imaging, Nanotechnology & Theranostics (CMINT)), two Clinical/Translational Research Programs (Signal Transduction & Therapeutics (STT); Tumor Immunology (TI)), one Population Science Research Program (Cancer Control & Survivorship (CCS)), six Shared Resources, an Office for Cancer Training and Education, and a Community Outreach and Engagement core. During 2013 ? 2018, the JCCC made substantial progress in its mission, with significant advances in many areas. Examples include improvements in prevention through vaccination, e-cigarette, and obesity education, in detection with a national screening trial in lung cancer, in treatment with 11 new, practice changing FDA- approved therapeutics in cell therapy, targeted therapy, and immunotherapy, and in survivorship with intervention studies for breast cancer survivors with severe insomnia and leadership in developing national guidelines for survivorship care. A generational transition in institutional and JCCC senior leadership, and a recent, comprehensive Strategic Planning activity, guide the next five years of Center progress, with an unprecedented increase in institutional support and historic organizational changes implemented to meet ongoing and emerging opportunities and challenges in a rapidly changing healthcare environment. An aspirational vision to eradicate cancer in LAC, the nation, and the world drives Center leaders and membership to address difficult but essential problems in cancer. In the next period, with our community partners, the JCCC will advance studies that aim to define individual cancer risk to inform prevention, treatment, and foster survivorship; decode the initiation and evolution of cancer; understand individual cancers at unprecedented levels to improve patient treatment and outcomes; and harness the body?s immune system to control and treat cancer.

Public Health Relevance

The UCLA Jonsson Comprehensive Cancer Center (JCCC) strategic mission is to accelerate discoveries that prevent and cure cancer. Through a deep and broad spectrum of impactful research endeavors, clinical and research education and training programs, and the highest quality of patient care in multiple academic and community settings, the JCCC seeks to reduce the burden of cancer throughout its Los Angeles County catchment area and the nation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016042-44
Application #
9936710
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Ptak, Krzysztof
Project Start
1996-12-01
Project End
2025-03-31
Budget Start
2020-04-01
Budget End
2021-03-31
Support Year
44
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Leoh, Lai Sum; Kim, Yoon Kyung; Candelaria, Pierre V et al. (2018) Efficacy and Mechanism of Antitumor Activity of an Antibody Targeting Transferrin Receptor 1 in Mouse Models of Human Multiple Myeloma. J Immunol 200:3485-3494
Hicks, Michael R; Hiserodt, Julia; Paras, Katrina et al. (2018) ERBB3 and NGFR mark a distinct skeletal muscle progenitor cell in human development and hPSCs. Nat Cell Biol 20:46-57
Tsang, Eric J; Wu, Benjamin; Zuk, Patricia (2018) MAPK signaling has stage-dependent osteogenic effects on human adipose-derived stem cells in vitro. Connect Tissue Res 59:129-146
Waters, Lynnea R; Ahsan, Fasih M; Wolf, Dane M et al. (2018) Initial B Cell Activation Induces Metabolic Reprogramming and Mitochondrial Remodeling. iScience 5:99-109
Van Dyk, Kathleen; Bower, Julienne E; Crespi, Catherine M et al. (2018) Cognitive function following breast cancer treatment and associations with concurrent symptoms. NPJ Breast Cancer 4:25
Robinett, Ryan A; Guan, Ning; Lux, Anja et al. (2018) Dissecting Fc?R Regulation through a Multivalent Binding Model. Cell Syst 7:41-48.e5
Chin, Chee Jia; Li, Suwen; Corselli, Mirko et al. (2018) Transcriptionally and Functionally Distinct Mesenchymal Subpopulations Are Generated from Human Pluripotent Stem Cells. Stem Cell Reports 10:436-446
Alban, Tyler J; Alvarado, Alvaro G; Sorensen, Mia D et al. (2018) Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. JCI Insight 3:
Yang, Qing; Fung, Wing K; Li, Gang (2018) Sample size determination for jointly testing a cause-specific hazard and the all-cause hazard in the presence of competing risks. Stat Med 37:1389-1401
Seo, Jai Woong; Tavaré, Richard; Mahakian, Lisa M et al. (2018) CD8+ T-Cell Density Imaging with 64Cu-Labeled Cys-Diabody Informs Immunotherapy Protocols. Clin Cancer Res 24:4976-4987

Showing the most recent 10 out of 767 publications